Join NCI: The ASCO Virtual Scientific Program Starts Today

NCI at ASCO 2020 Friday, May 29 Please join NCI experts during the ASCO virtual conference. Be sure to check out the full list of conference abstracts for details and additional sessions.

Tune in Tomorrow: Dr. Sharpless Presents: Cancer Care in the Time of COVID NCI Director Dr. Norman E. Sharpless will participate in the panel discussion, "Cancer Care in the time of COVID: Assessing the Impact and Future Directions." Tune in Tomorrow, May 30 at 4:30 p.m. ET Learn more about this session. NCI at ASCO20 NCI’s cancer research experts are participating in more than 80 poster sessions and presentations throughout the meeting. Watch them on-demand and be sure to check out the ASCO Meeting Library for details. Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers. NCI Participants: Christian Hinrichs, Scott Norberg, Nisha Nagarsheth, Andrew Sinkoe, Thomas Meyer, Jennifer Ann Kanakry, Nikolaos Gkitsas Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106. NCI Participant: Larissa Korde Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F NCI Participants: Lisa McShane, Larry V Rubinstein, Mickey Williams, Lyndsay Harris, Alice P. Chen, Keith Flaherty, David R Patton Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. NCI Participants: W Marston Linehan, Ramaprasad Srinivasan Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. NCI Participants: Ramaprasad Srinivasan, Sandeep Gurram, Munjid Al Harthy, Abhinav Sidana, Mark Wayne Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy Vocke, Peter L Choyke, Lori Long, Joanna Shih, Maria J Merino, W. Marston Linehan A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. NCI Presenter: Elise C Kohn Underdiagnosis and undertreatment of modifiable cardiovascular risk factors: A Childhood Cancer Survivor Study (CCSS) report. NCI Presenter: Todd M Gibson Neuroleptic rotation for refractory agitation in cancer patients with delirium in the acute palliative care unit: A double-blind randomized clinical trial. NCI Presenter: Terri Armstrong Connect with NCI at ASCO20 Visit our NCI at ASCO page for resources, funding opportunities, and more information on NCI's presence at ASCO's Virtual Scientific Program, or find us in the ASCO2020 Virtual Exhibit Hall! To join the discussion, follow NCI on Twitter at @theNCI and Instagram at @nationalcancerinstitute.